Evaluating a novel nanoparticle platform for controlled liraglutide release in a Type II diabetes mouse model

A large percentage of Type 2 diabetes mortality is related to cardiovascular complications. Consequently, there is a critical need for creating novel therapeutics that not only manage blood glucose levels, but also reduce the risk of developing cardiovascular diseases.

Liraglutide (Lira) is a recently approved drug used to treat Type II diabetes with excellent hypoglycemic effects while also improving cardiovascular function in patients. However its short half-life requires daily injections increasing the risk of poor patient compliance and other complications.

Read this publication review to learn how researchers used a Type II diabetes mouse model and optical imaging with the IVIS^® platform to evaluate a nanoparticle system that offers a sustained and controlled release of Lira that overcomes the challenges of the short half-life of the drug.

For research use only. Not for use in diagnostic procedures.